Skip to main content

Universal Influenza Vaccines Secured

Objective

UNISEC brings together a European consortium of 3 University partners, 5 National Health Institutes and 3 SMEs, all with leading expertise in influenza vaccine research and development, to work on promising recently developed concepts for a universal influenza vaccine. The consortium is exceptionally strong, interdisciplinary and intersectional in nature, and encompasses a unique combination of scientific and technological expertise from lead identification to clinical trial execution.

UNISEC will bring a number of vaccine concepts together into a single study in order to identify, develop and clinically test the 3 most promising leads for a universal influenza vaccine, which must (1) demonstrate adequate (universal) protection, and (2) be technically suitable for development to a marketable product.

Preclinical and clinical methodologies will be developed allowing a comparative evaluation of the vaccine concepts. Head-to-head comparisons in animal models will also be performed, with the most promising concepts to then be ready for clinical assessment. Independent comparative clinical studies will be executed and carried out by 5 established Clinical Trial Site partners.

The expected impact of the UNISEC work programme will be the resolution of current problems of non-uniformity in the development and evaluation of universal influenza vaccines in Europe by a unified approach using an expert and sustainable vaccine expertise network. The UNISEC results will directly contribute to a timely, longer-term, broader, more effective and cost-effective universal influenza vaccine for the prevention of annual and pandemic influenza.

The success of UNISEC will be based on the leading experience of its consortium partners; the proven track record of its clinical trial site partners; and a coherent and well-defined management structure and dissemination program, underpinned by the fact that several UNISEC partners were previously part of the successful EU FLUSECURE project.

Field of science

  • /medical and health sciences/health sciences/infectious disease/RNA virus/influenza
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

RIJKSUNIVERSITEIT GRONINGEN
Address
Broerstraat 5
9712CP Groningen
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 345 917,76
Administrative Contact
Dick Veldhuis (Dr.)

Participants (12)

ACADEMISCH ZIEKENHUIS GRONINGEN
Netherlands
EU contribution
€ 601 066,80
Address
Hanzeplein 1
9713 GZ Groningen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Johanna M Van Apeldoorn (Mrs.)
PEPTCELL LTD
United Kingdom
EU contribution
€ 721 127,91
Address
Fetter Lane 100
EC4A 1BN London
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Gregory Stoloff (Mr.)
BIONDVAX PHARMACEUTICALS LTD
Israel
EU contribution
€ 564 557,75
Address
Einstein Street 14
74036 Nes Ziona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Tanya Gottlieb (Dr.)
RETROSCREEN VIROLOGY LTD
United Kingdom
EU contribution
€ 25 317,60
Address
New Road Queen Mary Bioenterprise Innovation Centre 42
E1 2AX London
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
John Oxford (Prof.)
Department of Health
United Kingdom
EU contribution
€ 485 631,75
Address
Quarry House, Quarry Hill
LS2 7UE Leeds
Activity type
Research Organisations
Administrative Contact
Amanda King (Ms.)
STATENS SERUM INSTITUT
Denmark
EU contribution
€ 547 233,60
Address
Artillerivej 5
2300 Kobenhavn S
Activity type
Research Organisations
Administrative Contact
Dennis Christensen (Dr.)
ORSZAGOS EPIDEMIOLOGIAI KOZPONT
Hungary
EU contribution
€ 358 610,80
Address
Albert Florian Utca 2-6
1097 Budapest
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Ildiko Visontai (Dr.)
FOLKEHELSEINSTITUTTET
Norway
EU contribution
€ 356 791,20
Address
Lovisenberggata 8
0456 Oslo
Activity type
Research Organisations
Administrative Contact
Kjerstin Klevdal Nielsen (Mrs.)
ROBERT KOCH-INSTITUT
Germany
EU contribution
€ 538 225,67
Address
Nordufer 20
13353 Berlin
Activity type
Research Organisations
Administrative Contact
Birgit Arnold (Mrs.)
GOETEBORGS UNIVERSITET
Sweden
EU contribution
€ 427 699,66
Address
Vasaparken
405 30 Goeteborg
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Ellen Rydberg (Dr.)
NOVAVAX AB

Participation ended

Sweden
Address
Kungsgatan 109
753 18 Uppsala
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Erik Bergman (Mr.)
Medicines and Healthcare products Regulatory Agency

Participation ended

United Kingdom
Address
Buckingham Palace Road
SW1W 9SZ London
Activity type
Research Organisations
Administrative Contact
Amanda King (Ms.)